Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma

Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib and transhepatic arterial chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Lei, Cai, Xingchen, Mugaanyi, Joseph, Liu, Yelei, Mao, Shuqi, Lu, Changjiang, Lu, Caide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492645/
https://www.ncbi.nlm.nih.gov/pubmed/34611195
http://dx.doi.org/10.1038/s41598-021-98937-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492645/
https://www.ncbi.nlm.nih.gov/pubmed/34611195
http://dx.doi.org/10.1038/s41598-021-98937-2

Ejemplares similares